Home Newsfeeds Stephens & Co. Maintains Overweight on Builders FirstSource, Raises Price Target to $90

Stephens & Co. Maintains Overweight on Builders FirstSource, Raises Price Target to $90

Stephens & Co. analyst Trey Grooms maintains Builders FirstSource (NYSE:BLDR) with a Overweight and raises the price target from $75 to $90.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Stephens & Co. analyst Trey Grooms maintains Builders FirstSource (NYSE:BLDR) with a Overweight and raises the price target from $75 to $90.

News
Tech

Tesla Upgrades Model Y In China With Advanced Self-Driving Hardware 4, No Price Increase

By Anan Ashraf

February 1, 12:21 AM

EV giant Tesla Inc (NASDAQ:TSLA) has introduced self-driving hardware version 4 on its Model Y SUVs in China.…

TSLA

BorgWarner Shares Tumble Despite Strong Q1 Sales, Expansion Plans For Seneca Facility Announced

By Nabaparna Bhattacharya

May 4, 12:28 PM

BorgWarner Inc (NYSE: BWA) reported first-quarter FY23 sales growth of 8% year-on-year to $4.18 billion,

BWA

AIM ImmunoTech Announces FDA Clearance Of IND Application To Evaluate Ampligen In Phase 2 Clinical Study For The Treatment Of Post-COVID Conditions

By Benzinga Newsdesk

October 12, 8:46 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

Nike Q1 Earnings Highlights: Revenue And EPS Beat, Investors Pull Back On Inventory, China Concerns

By Chris Katje

September 29, 4:34 PM

Apparel and footwear company Nike Inc (NYSE: NKE) reported first-quarter financial results after market close Thursday. Here are the key highlights for Nike investors.

NKE

Stephens & Co. Maintains Overweight on Builders FirstSource, Raises Price Target to $90

Related Posts

Tesla Upgrades Model Y In China With Advanced Self-Driving Hardware 4, No Price Increase

BorgWarner Shares Tumble Despite Strong Q1 Sales, Expansion Plans For Seneca Facility Announced

AIM ImmunoTech Announces FDA Clearance Of IND Application To Evaluate Ampligen In Phase 2 Clinical Study For The Treatment Of Post-COVID Conditions

Nike Q1 Earnings Highlights: Revenue And EPS Beat, Investors Pull Back On Inventory, China Concerns